IXICO plc Extension of Huntington's disease consortium (1157V)
April 03 2023 - 2:35AM
UK Regulatory
TIDMIXI
RNS Number : 1157V
IXICO plc
03 April 2023
3 April 2023
IXICO plc
("IXICO" or the "Company")
Extension of Huntington's disease consortium worth circa GBP1
million
IXICO plc (AIM: IXI), the neuroimaging Contract Research
Organisation (CRO) delivering advanced AI analytical insights in
neuroscience, is pleased to announce it has secured additional
contract orders to support completion of the retrospective analysis
of over 6,000 HD imaging datasets through the Huntington's Disease
Imaging Harmonization Consortium (HD-IH), previously announced on
21(st) September 2022. HD is a rare, inherited neurodegenerative
disease that causes the progressive breakdown of nerve cells in the
brain affecting movement, mood and thinking abilities. There are no
existing approved disease modifying therapies for HD, nor
interventions that slow disease progression.
The output of the project will enable current and prospective
consortium partners together with their collaborators to develop
improved approaches to stratifying patients in HD clinical trials
as well as increasing the precision of efficacy measurements of
drugs within HD clinical trials. IXICO is delivering this analysis
to the biopharma and charitable foundation consortium members using
its proprietary, deep learning based, IXIQ.Ai analysis platform.
Additional financial contribution has been secured from two
partners, where one is a new consortium member and the other, an
existing consortium member, enabling completion by June 2025. The
consortium partners remain open for additional partners to join to
benefit from the analysis already undertaken and to further
accelerate completion of the project.
Giulio Cerroni, Chief Executive Officer of IXICO, commented : "
The HD-IH consortium is working on the development of new standards
for imaging in HD through the analysis and interpretation of
existing HD imaging datasets. We are very excited to build
additional momentum in the consortium and look forward to working
closely with our existing and new partners towards the development
of novel imaging tools that enable the design of more efficient HD
clinical trials.
The development of new imaging standards in this consortium
further cements IXICO's position as the leading analysis company
for HD as part of its wider portfolio of leading analytical tools
to support clinical trials into neurological diseases."
For further information please contact:
IXICO plc +44 (0)20 3763 7499
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Tamar Cranford-Smith
(Sales)
About IXICO | Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in neuroscience to
help transform the advancement of investigational therapies for
neurological diseases, such as Huntington's, Parkinson's,
Alzheimer's disease and Multiple Sclerosis. The Company's purpose
is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights
in neuroscience by supporting pharmaceutical companies across all
phases of CNS clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning
Ai data analytics, at scale, through its remote access TrialTracker
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on
Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTSSESWDEDSEDL
(END) Dow Jones Newswires
April 03, 2023 03:35 ET (07:35 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Ixico (LSE:IXI)
Historical Stock Chart
From Feb 2024 to Feb 2025
